Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, Massa M, Rosti V, Campanelli R, Villani L, Viarengo G, Gattoni E, Gerli G, Specchia G, Tinelli C, Rambaldi A, Barbui T; Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Italian Registry of Myelofibrosis.

Blood. 2007 Dec 1;110(12):4030-6. Epub 2007 Aug 21.

2.

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M.

Leukemia. 2010 Sep;24(9):1574-9. doi: 10.1038/leu.2010.148. Epub 2010 Jul 15.

PMID:
20631743
3.

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Eur J Haematol. 2007 Dec;79(6):508-15. Epub 2007 Oct 23.

PMID:
17961178
4.

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.

Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17.

PMID:
19616600
5.

Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques.

Veneri D, Capuzzo E, de Matteis G, Franchini M, Baritono E, Benati M, Solero GP, Ambrosetti A, Quaresmini G, Pizzolo G.

Blood Transfus. 2009 Jul;7(3):204-9. doi: 10.2450/2009.0070-08.

6.

JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.

Mesa RA, Powell H, Lasho T, Dewald G, McClure R, Tefferi A.

Leuk Res. 2006 Nov;30(11):1457-60. Epub 2006 Mar 23.

PMID:
16563504
7.

Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.

Ohyashiki K, Kodama A, Ohyashiki JH.

Cancer Genet Cytogenet. 2008 Oct;186(1):6-11. doi: 10.1016/j.cancergencyto.2008.04.021.

PMID:
18786436
8.

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.

Helbig G, Wieczorkiewicz A, Woźniczka K, Wiśniewska-Piąty K, Rusek A, Kyrcz-Krzemień S.

Med Oncol. 2012 Dec;29(4):2379-84. doi: 10.1007/s12032-012-0190-3. Epub 2012 Mar 1.

PMID:
22383244
9.

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.

Hsieh PP, Olsen RJ, O'Malley DP, Konoplev SN, Hussong JW, Dunphy CH, Perkins SL, Cheng L, Lin P, Chang CC.

Mod Pathol. 2007 Sep;20(9):929-35. Epub 2007 Jul 20.

10.

JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy.

Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ, Cross NC.

Leuk Res. 2011 Feb;35(2):177-82. doi: 10.1016/j.leukres.2010.06.017. Epub 2010 Jul 22.

11.

JAK2V617F allele burden is associated with transformation to myelofibrosis.

Koren-Michowitz M, Landman J, Cohen Y, Rahimi-Levene N, Salomon O, Michael M, Amariglio N, Nagler A.

Leuk Lymphoma. 2012 Nov;53(11):2210-3. doi: 10.3109/10428194.2012.682308. Epub 2012 May 21.

PMID:
22524513
12.

Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.

Patriarca A, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A.

Blood Transfus. 2010 Jan;8(1):21-7. doi: 10.2450/2009.0004-09.

13.

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.

Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E, Pieri L, Pancrazzi A, Ponziani V, Delaini F, Longo G, Ammatuna E, Liso V, Bosi A, Barbui T, Vannucchi AM.

Blood. 2009 Aug 20;114(8):1477-83. doi: 10.1182/blood-2009-04-216044. Epub 2009 Jun 23.

14.

The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.

Lucia E, Martino B, Mammi C, Vigna E, Mazzone C, Gentile M, Qualtieri G, Bisconte MG, Naccarato M, Gentile C, Laganà C, Romeo F, Neri A, Nobile F, Morabito F.

Leuk Lymphoma. 2008 Oct;49(10):1907-15. doi: 10.1080/10428190802290652.

PMID:
18720212
15.

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.

Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K.

BMC Med Genet. 2012 Jan 17;13:6. doi: 10.1186/1471-2350-13-6.

16.

Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.

Kreft A, Springer E, Lipka DB, Kirkpatrick CJ.

Acta Haematol. 2009;122(1):36-8. doi: 10.1159/000235773. Epub 2009 Aug 28.

PMID:
19713696
17.

A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.

Poodt J, Fijnheer R, Walsh IB, Hermans MH.

Hematol Oncol. 2006 Dec;24(4):227-33.

PMID:
17006961
18.

Decreased JAK2 V617F allele burden level in a myelofibrosis with myeloid metaplasia patient with leukemic transformation.

Wu YY, Hung HM, Chen TS, Chao TY, Ho CL.

Leuk Res. 2008 Nov;32(11):1783-6. doi: 10.1016/j.leukres.2008.03.015. Epub 2008 May 2. No abstract available.

PMID:
18455791
19.

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.

N Engl J Med. 2005 Apr 28;352(17):1779-90.

20.

Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.

Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O.

Ann Hematol. 2007 Apr;86(4):245-53. Epub 2007 Jan 30.

PMID:
17262192
Items per page

Supplemental Content

Write to the Help Desk